Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results
An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as nonurothelial tract recurrence-free survival (NUTRFS), distant metastasis-free survival (DMFS), and second progression-free survival (PFS2). An exploratory analysis assessed outcomes in the muscle-invasive urothelial carcinoma (MIBC) subgroup, prior neoadjuvant chemotherapy (NAC) use, and PD-L1 expression. This analysis was conducted to further evaluate efficacy across subgroups and refine the understanding of treatment impact.
Video Player is loading.
Video content above is prompted by the following:
- Please review the updated results from CheckMate 274. (Galsky 2025)
- Updated DFS and interim OS
- Other end points (eg, NUTRFS, DMFS, PFS2)
- Exploratory analysis of MIBC subgroup, prior NAC, PD-L1 expression
- Why was this analysis performed?
Recent Videos
Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing
Adjuvant ICI for High-Risk MIUC: Patient Counseling
Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management
Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting
Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies
Dr. Galsky’s Perspectives on the CheckMate 274 Data Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design
High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy
MIUC: Risk of Recurrence After Radical Cystectomy
Related Content
